• To ensure your request is directed to the right business and data integration team, please ensure you complete all the questions on the application form as fully as possible.
  • Once you have spoken to a member of the business team, MIMS Australia will send you a Mutual Non-Disclosure Agreement (MNDA) and provide more information to help you understand the process for access and evaluation of the data.
  • There is an initial one-off integration / conformance fee for all partner applicants for MIMS technical and clinical assistance with integrating the MIMS Medicines Database into a third-party application. This will be charged prior to you being provided with access to any of the MIMS data and is non-refundable. Your relevant BDM will be happy to discuss this further.
  • Please read the MNDA documents carefully then sign and return a scanned copy of the MNDA marked to the attention of: Your relevant Business Development Manager (BDM).
  • Once the MNDA has been signed and returned, we will introduce you to our Solutions Delivery / Data Integration Team. This team will organise a workshop to discuss the MIMS data base in detail, gather your integration requirements and help with any issues or concerns you may have. The team will also stay in touch throughout your development to support you through the process, and guide on how to best integrate the data.
  • Permission for use of the MIMS data base for development is granted for 6 months. After this six-month period if we have not heard from you, your access will be terminated. If you require access for a longer period, you will need to apply for an extension by contacting your BDM.
  • During your development/integration, your BDM will be working with you or your nominated business contact to agree on commercials and licensing of the MIMS data and the on-going annual fees.
  • Once the MNDA has been signed by both parties we are happy to discuss the commercials and advise you of this before you start the development. It is your responsibility to ensure you fully understand our fee structure and how it fits into your business model.
  • The provision of ongoing Monthly updated MIMS data is contingent on two important steps that must be taken prior to deployment of your final integration of our data base to your end users:
1. All licensing agreements and commercials between MIMS and your organisation must have been negotiated, agreed to and the Licence Agreement signed by both parties
2. The MIMS Data Team must review and approve the integration of MIMS data within your software.

Once everything has been completed, you will be notified in writing of the approval to deploy your software with MIMS integrated data.
MIMS Australia
Suite 1602, 44 Market Street
Sydney
NSW 2000
+61 2 9902 7700
www.mims.com.au


Question Title

1. Company Name

Question Title

2. ABN

Question Title

3. Address

Question Title

4. Postal Address if different from above

Question Title

5. Phone

Question Title

6. Company website

Question Title

7. Details of existing products and solutions. Please include product website if different from company website.

Question Title

8. Business contact

Question Title

9. Technical or project lead contact

Question Title

10. Is the development/ integration team employed with in your organisation

Question Title

11. If you are using any outsourced outside development/ integration contractor(s)/ sub-contractors(s), please provide contact details

Question Title

12. What are your existing or intended software functionalities? Please include all that apply

Question Title

13. Who are your intended user bases? Please highlight all relevant options

Question Title

14. What are your existing or intended systems architectures and deployment platforms?
Please select all relevant options.

Question Title

15. What is your software development stack? In case any artificial intelligence (AI) technologies are in use, please also describe your AI stack.

Question Title

16. Briefly describe your information security management system (ISMS) policy and maturity level (e.g. ISO 27001 (Intl), ACSC ISM (AU), ENISA EUCC (EU), NCSC Cyber Essentials (UK), NIST CSF (US)). In case you are using any outsourced development/integration contractor(s)/sub-contractor(s), please also describe how downstream ISMS compliance is enforced.

Question Title

17. Do you currently (or intend to) maintain your own local drug database? If yes, please briefly describe the use case for offline storage of MIMS Integrated data. In case any AI technologies are in use, please also describe how MIMS data (alongside with any other data sources, if applicable) will be consumed by your AI model.

Question Title

18. Briefly describe how MIMS Integrated medicines information and clinical decision support will be used in your software, including how different user types (e.g. prescriber vs. non-prescribing staff, provider vs. consumer) will be using MIMS Integrated functions. In case any AI technologies are in use, please also describe the AI assisted functions.

Question Title

19. What is the expected start date for integration of MIMS Integrated?

Question Title

20. What is your expected launch date of your software with MIMS Integrated.

Page1 / 1
 
 100% of survey complete.
( Privacy & Cookie Notice

T